374 related articles for article (PubMed ID: 9010834)
21. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
22. Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive patients.
Luchsinger A; Grilli M; Forte P; Morales E; Velasco M
Int J Clin Pharmacol Ther; 1995 Sep; 33(9):509-12. PubMed ID: 8520809
[TBL] [Abstract][Full Text] [Related]
23. The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman.
Verhelst J; Beckers A; Abs R
Fertil Steril; 1995 Nov; 64(5):969-71. PubMed ID: 7589643
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of hypothalamic dopaminergic function in patients with pituitary prolactinoma.
Xia P; Shi YF
Proc Chin Acad Med Sci Peking Union Med Coll; 1989; 4(3):121-5. PubMed ID: 2594732
[TBL] [Abstract][Full Text] [Related]
25. When to discontinue treatment of prolactinoma?
Wass JA
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):298-9. PubMed ID: 16932302
[No Abstract] [Full Text] [Related]
26. [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case].
García Calzado MC; Ruiz Buendía A
Rev Clin Esp; 1992 Jun; 191(2):112-3. PubMed ID: 1502384
[No Abstract] [Full Text] [Related]
27. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
29. [Increased T1 signal of the residual normal anterior pituitary gland following medical treatment of pituitary prolactinoma].
Bonneville F; Cattin F; Barrali E; Lucas X; Narboux Y; Bonneville J
J Radiol; 2001 Apr; 82(4):501-5. PubMed ID: 11353909
[TBL] [Abstract][Full Text] [Related]
30. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
31. [The effect of oxcarbamazepine on the clinical effectiveness of dopamine agonists in the treatment of prolactinoma].
Krysiak R; Kedzia A; Okopień B
Wiad Lek; 2011; 64(4):279-82. PubMed ID: 22533152
[TBL] [Abstract][Full Text] [Related]
32. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
33. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Delgrange E; Crabbé J; Donckier J
Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
[TBL] [Abstract][Full Text] [Related]
34. Selectivity of metoclopramide for endocrine versus renal effects of dopamine in normal humans.
Blumberg AL; Dubb JW; Allison NL; Aldins Z; Ramey K; Stote RM
J Cardiovasc Pharmacol; 1988 Feb; 11(2):181-6. PubMed ID: 2452312
[TBL] [Abstract][Full Text] [Related]
35. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
36. Sjögren's Syndrome Accompanied by Prolactinoma: a case report and literature review.
Oh YJ; Lee WS; Yoo WH; Hahm JR; Kim HO; Suh YS; Lee SI; Cheon YH
Int J Rheum Dis; 2017 Nov; 20(11):1823-1826. PubMed ID: 26355497
[No Abstract] [Full Text] [Related]
37. Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.
Sowers J; Catania R; Paris J; Tuck M
J Clin Endocrinol Metab; 1982 Mar; 54(3):510-6. PubMed ID: 7035482
[TBL] [Abstract][Full Text] [Related]
38. Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia.
Serri O
Horm Res; 1987; 27(1):36-41. PubMed ID: 3623428
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
40. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
